Send
Send
Print
Print

Press Releases

Flux RSS
 
25/08/10
BacT/ALERT Press Release
The bioMerieux BacT/ALERT microbial detection system has been selected by the mcirobiology laboratory at the Royal Oldham hospital for processing blood cultures.
Read More
14/07/2010
Clinical Product List

Read More
May 21, 2010
Shimadzu and bioMérieux Enter into Partnership for Mass Spectrometry Applications in Microbiology
Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimized integration into the microbiology laboratory workflow. This new solution is planned for commercialization by bioMérieux in 2010, together with the microbial database acquired from AnagnosTec.
Read More
April 12, 2010
bioMérieux Introduces Myla™ at ECCMID: New Informatics Solution to Transform the Microbiology Laboratory
Innovative software:
  • consolidates and transforms microbiology laboratory data into actionable information for treatment decisions
  • recaptures time for lab managers through efficiency gains and full control of lab workflow
A world leader in in vitro diagnostics, bioMérieux presented Myla™, a paradigm-shifting software application, at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria. Myla is a browser-based application that provides microbiology laboratory managers and technicians with a set of tools to revolutionize the way they work. It was designed by microbiologists for microbiologists to recapture the time spent on information retrieving and reporting activities through improved connectivity, laboratory workflow and information management. For more information, visit www.mylahelps.com.
Read More
November 6, 2009
bioMérieux Launches a Molecular Diagnostic MRSA Test on its EasyQ® Automated Platform
Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010.
Read More
June 30, 2009
bioMérieux Launches VIDAS® EBV, a New Test for the Diagnosis of Infectious Mononucleosis
bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva.
Read More
June 1, 2009
Data from Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
- THEROS CancerTYPE ID® predicts cancer origin with 75 percent accuracy in patients whose primary cancer was “unknown” using traditional diagnostics. -
bioTheranostics, a bioMérieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company’s THEROS CancerTYPE ID® molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially “unknown” using traditional diagnostics. Findings were presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl.
Read More
May 19, 2009
bioMérieux Launches Molecular Biology Test, NucliSENS EasyQ® HIV-1 v2.0, for Improved Care of Patients with HIV

New test can be used with the first CE marked Dry Blood Spot sample collection technique for viral load monitoring, bringing testing to patients in remote locations
bioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today.
Read More
May 15, 2009
bioMérieux: Enhancing the Productivity of Microbiology Laboratories with the LeanSigma® Method
bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology.
Read More
May 12, 2009
2009 ESCMID/bioMérieux Research Grant in Clinical Microbiology

Winner Conducting Research on Major Cause of Healthcare-Associated Infections
bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe.
Read More